← Volver a la portada
Estados Unidos · Plataformas y datos · Finviz

Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation ...

Publicado por Finviz · Estados Unidos hace 15 h

CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE)-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that results from its Phase 1b…

Leer el artículo completo en Finviz Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (finviz.com)

También te puede interesar

MarketBeat

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

 Seeking Alpha

Tech borrowers are picking up the tab: debt premium hits a 23-year high

 CNBC

Texas governor race tightens in prediction markets, but Abbott remains favored

 MarketWatch

‘It’s good to be old’: I’ve been invited to a dozen free meals that turn into annuity sales pitches. Should I stop going?

 The Motley Fool

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

 Investing.com

Treasury yields edge up as Election Day meets JOLTS, refunding